Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

Multiple myeloma remains an incurable disease with the usual disease course requiring
induction therapy, autologous stem cell transplantation for eligible patients, and long-term …

CANDOR (NCT03158688) is a phase 3, randomized, open-label trial comparing carfilzomib,
daratumumab, and dexamethasone (KdD) vs carfilzomib and dexamethasone (Kd) in adults …

PURPOSE With the initial analysis of POLLUX at a median follow-up of 13.5 months,
daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly …

Simple Summary Macrophages are the “big eaters” of the immune system who are in charge
of engulfing undesirable substances. Macrophages are vital for the human body as they are …

Background The outcome of non-transplant eligible newly diagnosed multiple myeloma
(NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study …

Simple Summary Multiple myeloma is an incurable hematologic malignancy arising from
terminally differentiated B-cells. Over the last decade, advancements in therapeutics have …

Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …

Background The financial impact of cancer medicines on health systems is not well known.
We describe temporal trends in expenditure on cancer medicines within the single-payer …

Background The primary analysis of the APOLLO trial, done after a median follow-up of 16· 9
months, showed that daratumumab plus pomalidomide and dexamethasone significantly …